On May, 3 EyePoint Pharmaceuticals, Inc. (PSDV) Analysts See $-0.13 EPS

April 16, 2018 - By Alex Paulin

EyePoint Pharmaceuticals, Inc. (NASDAQ:PSDV) Corporate Logo
Big Money Sentiment increased to 0.92 in Q4 2017. It has change of 0.30, from 2017Q3’s 0.62. The ratio is positive due to EyePoint Pharmaceuticals, Inc. positioning: 7 sold and 6 reduced. 5 funds amassed stakes and 7 increased stakes. Investors holded 4.35 million in 2017Q3 but now own 4.79 million shares or 10.05% more.
Vanguard Group invested in 1.57 million shs. Moreover, Atlantic Tru Gru Ltd Limited Liability Company has 0% invested in EyePoint Pharmaceuticals, Inc. (NASDAQ:PSDV) for 300 shs. Essex Inv Communications Ltd Liability accumulated 160,612 shs. Susquehanna Llp holds 0% in EyePoint Pharmaceuticals, Inc. (NASDAQ:PSDV) or 74,875 shs. Blackrock stated it has 126,505 shs. Paragon Capital Management Ltd owns 22,750 shs or 0.01% of their US capital. B & T Capital Management Dba Alpha Capital Management owns 0.01% invested in EyePoint Pharmaceuticals, Inc. (NASDAQ:PSDV) for 18,900 shs. Geode Management Ltd Co has 0% invested in EyePoint Pharmaceuticals, Inc. (NASDAQ:PSDV). Citadel Limited Liability Corp reported 15,691 shs. Utd Cap Finance Advisers Ltd Co holds 10,000 shs. Morgan Stanley, a New York-based fund reported 274,333 shs. Creative Planning owns 35,000 shs. Renaissance Technology Lc has 0% invested in EyePoint Pharmaceuticals, Inc. (NASDAQ:PSDV) for 1.52 million shs. The Illinois-based Bard Assoc Inc has invested 0.04% in EyePoint Pharmaceuticals, Inc. (NASDAQ:PSDV). 101,900 are owned by Bridgeway Capital Management.

EyePoint Pharmaceuticals, Inc. had 0 sales and 1 insider buy since March 28, 2018. This’s net activity of $9.47 million.

On May, 3. Investors expect EyePoint Pharmaceuticals, Inc. (NASDAQ:PSDV) to report its quarterly earnings, as reported by Faxor. This year’s earnings per share analyst estimate is awaited to be $-0.13. That is 13.33 % up compareed to $-0.15 earnings per share for last year. Wall Street predicts 0.00 % EPS growth as of May, 3. The stock increased 14.02% or $0.15 during the last trading session, reaching $1.22.EyePoint Pharmaceuticals, Inc. has 1.18 million shares volume, 210.23% up from normal. PSDV is downtrending and has moved 35.47% since April 16, 2017. PSDV underperformed by 47.02% the S&P500.

EyePoint Pharmaceuticals, Inc. (NASDAQ:PSDV) Ratings Coverage

Total analysts of 3 have positions in pSivida (NASDAQ:PSDV) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 8, 2017 according to StockzIntelligence Inc pSivida has 8 analyst reports. In Monday, February 5 report FBR Capital initiated the stock with “Buy” rating. On Wednesday, November 8 the rating was maintained by H.C. Wainwright with “Buy”. On Tuesday, March 20 H.C. Wainwright maintained EyePoint Pharmaceuticals, Inc. (NASDAQ:PSDV) rating. H.C. Wainwright has “Buy” rating and $5.0 target. On Friday, December 15 the stock of EyePoint Pharmaceuticals, Inc. (NASDAQ:PSDV) has “Buy” rating given by H.C. Wainwright. The company rating was maintained by H.C. Wainwright on Tuesday, January 9. On Thursday, February 8 the stock of EyePoint Pharmaceuticals, Inc. (NASDAQ:PSDV) earned “Buy” rating by H.C. Wainwright.

pSivida Corp. develops sustained-release drug-delivery products for the treatment of chronic eye diseases in the United States and the United Kingdom.The company has $55.21 million market cap. It offers ILUVIEN, an injectable, sustained-release micro-insert for use in treating vision impairment associated with diabetic macular edema; and Retisert for the treatment of posterior segment uveitis.Last it reported negative earnings. The firm is also developing Durasert, an injectable, sustained-release micro-insert, which is in Phase III clinical trials for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.

EyePoint Pharmaceuticals, Inc. (NASDAQ:PSDV) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.